Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 26Gliosarcoma 22Glioblastoma 21Glioma 16Ependymoma 15Astrocytoma 12Osteosarcoma 11Oligodendroglioma 11Central Nervous System Neoplasms 10Rhabdomyosarcoma 9Medulloblastoma 9Sarcoma, Ewing 7Neuroblastoma 7Glioma, Subependymal 7Brain Neoplasms 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Carcinosarcoma 6Wilms Tumor 5Liposarcoma 5Hepatoblastoma 5Carcinoma, Transitional Cell 5Sarcoma, Kaposi 4Ovarian Neoplasms 4Meningioma 4

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Mohs Surgery 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × Magnetic Resonance Spectroscopy × Sarcoma × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡